Evidence map›Paper›PMID 22052471›Full record

ReviewHeart failure reviews2012

Atrial fibrillation and heart failure in the elderly.

Pedram Kazemian, Gavin Oudit, Bodh I Jugdutt

Abstract readReview
PubMed Publisher
In one paragraph

Review in Heart failure reviews, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Observational
  7. Article
  8. Article
  9. Article
  10. Safety and efficacy of cryoballoon ablation for the treatment of atrial fibrillation in elderly patients.Clinical research in cardiology : official journal of the German Cardiac Society · 2019
    Article
  11. Atrial fibrillation in aging population.Aging medicine (Milton (N.S.W)) · 2018
    Review
  12. Article
  13. Article
  14. Article
  15. Review
  16. Observational
  17. Observational
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Pedram KazemianDepartment of Medicine, Walter MacKenzie Health Sciences Centre, Division of Cardiology, University of Alberta and Hospital, Edmonton, AB, Canada.
Gavin Oudit
Bodh I Jugdutt

Funding

Canadian Institutes of Health Research IAP-99003
6 · The paper itself

Abstract

Atrial fibrillation (AF) is a common clinical problem in elderly patients and especially in those with heart failure (HF). It is a major risk factor for serious cardiovascular events, such as stroke, HF and premature death. Both the prevalence and incidence of AF increase with age and its prevalence in the United States are estimated at more than 2.2 million, with nearly 75% of patients aged >65 years. Aging-related atrial remodeling with fibrosis, dilation and mitochondrial DNA mutations predispose elderly patients to AF. Current management options for AF, including rate control and anticoagulation therapy, can be successfully applied to the elderly population. New antiarrhythmic and anticoagulation medications such as dronedarone and dabigatran, respectively, can impact the approach to therapy in the elderly. Non-pharmacological options such as catheter-based ablation have also gained prominence and have been incorporated into the guidelines for management of AF. However, more trials in the elderly and very elderly segments are needed to clarify the safety and long-term efficacy of the new treatment options.

Indexed as

AgedAged, 80 and overAgingAnti-Arrhythmia AgentsAnticoagulantsAtrial FibrillationCatheter AblationHeart FailureHeart RateHumansRisk FactorsAnti-Arrhythmia AgentsAnticoagulants

Identifiers

PMID22052471

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.